Opinion|Videos|April 11, 2024

Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics

Diana Brixner, PhD, FAMCP, examines the payer perspective on including Prescription Digital Therapeutics in formularies, utilizing real-world evidence as a key metric to assess the impact, cost-effectiveness, and patient benefit of these innovative digital treatments.


Related to this article

8 takeaways from the MHE and Drug Topics post-midterms webinar
Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.